Advanced glycation end-products suppress neuropilin-1 expression in podocytes

Kidney International

Volumn 75, Issue 6, 2009, Pages 605-616

  Bondeva, Tzvetanka ^a   Rüster, Christiane ^a   Franke, Sybille ^a   Hammerschmid, Elke ^a   Klagsbrun, Michael ^b   Cohen, Clemens D ^c   Wolf, Gunter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Advanced glycation end products; Diabetic nephropathy; Neuropilin 1; Podocytes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; NEUROPILIN 1; NEUROPILIN 2; PLEXIN; SEMAPHORIN 3A; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BOWMAN CAPSULE; CELL DIFFERENTIATION; CELL MIGRATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIFFERENTIAL DISPLAY; DOWN REGULATION; FOCAL GLOMERULOSCLEROSIS; GENE OVEREXPRESSION; GLOMERULUS; HUMAN; KIDNEY BIOPSY; KIDNEY TUBULE CELL; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGAN DONOR; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY; MICE; NERVE TISSUE PROTEINS; NEUROPILIN-1; NEUROPILIN-2; PODOCYTES; RECEPTORS, CELL SURFACE; RNA, MESSENGER; SEMAPHORIN-3A; SERUM ALBUMIN, BOVINE;

EID: 61349190949     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.603     Document Type: Article

References (47)

1. Brownlee M. Glycation and diabetic complications. Diabetes 1994; 43: 836-841.
2. Bohlender JM, Franke S, Stein G et al. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005; 289: F645-F659.
3. Thomas MC, Forbes JM, Cooper ME. Advanced glycation end products and diabetic nephropathy. Am J Ther 2005; 12: 562-572.
4. Wendt TM, Tanji N, Guo J et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-1137.
5. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 2007; 106: p26-p31.
6. Dalla Vestra M, Saller A, Mauer M et al. Role of mesangial expansion in the pathogenesis of diabetic nephropathy. J Nephrol 2001; 14(Suppl 4): S51-S57.
7. Van den Born J, Pisa B, Bakker MA et al. No change in glomerular heparan sulfate structure in early human and experimental diabetic nephropathy. J Biol Chem 2006; 281: 29603-29613.
8. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634.
9. Nosadini R, Velussi M, Brocco E et al. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 2000; 49: 476-484.
10. Hoshi S, Shu Y, Yoshida F et al. Podocyte injury promotes progressive nephropathy in Zucker diabetic fatty rats. Lab Invest 2002; 82: 25-35.
11. Kriz W, Gretz N, Lemely KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54: 687-697.
12. Mundel P, Reiser J, Zuniga Mejia Borja A et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-258.
13. ε-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am J Kidney Dis 2006; 48: 571-579.
14. ε-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor blocker II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron Clin Pract 2008; 108: c291-c297.
15. Valencia JV, Weldon SC, Quinn D et al. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal Biochem 2004; 324: 68-78.
16. Guan F, Villegas G, Teichman J et al. Autocrine class 3 semaphorin system regulates slit diaphragm proteins and podocyte survival. Kidney Int 2006; 69: 1564-1569.
17. Harper SJ, Xing CY, Whittle C et al. Expression of neuropilin-I by human glomerular epithelial cells in vitro and in vivo. Clin Sci 2001; 101: 439-446.
18. Wolf G, Haberstroh U, Neilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 1992; 140: 95-107.
19. Haverty TP, Kelly CJ, Hines WH et al. Characterization of a renal tubular epithelial cell line which secretes the autologous target antigen of autoimmune experimental interstitial nephritis. J Cell Biol 1988; 107: 1359-1368.
20. Soker S, Miao HQ, Nomi M et al. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 2002; 85: 357-368.
21. Bagri A, Tessier-Lavigne M. Neuropilins as Semaphorin receptors: in vivo functions in neuronal cell migration and axon guidance. Adv Exp Med Biol 2002; 515: 13-31.
22. Gallichio MA, McRobert EA, Tikoo A et al. Advanced glycation end products inhibit tubulogenesis and migration of kidney epithelial cells in an ezrin-dependent manner. J Am Soc Nephrol 2006; 17: 414-421.
23. Kreuter M, Bielenberg D, Hida Y et al. Role of neuropilins and semaphorins in angiogenesis and cancer. Ann Hematol 2002; 81(Suppl 2): S74.
24. Chen G, Sima J, Jin M et al. Semaphorin-3A guides radial migration of cortical neurons during development. Nat Neurosci 2008; 11: 36-44.
25. Eremina V, Cui S, Gerber H et al. Vascular endothelial growth factor A signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 2006; 17: 724-735.
26. Foster RR, Hole R, Anderson K et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol 2003; 284: F1263-F1273.
27. Allombert-Blaise C, Tamiji S, Mortier L et al. Terminal differentiation of human epidermal keratinocytes involves mitochondria- and caspase-dependent cell death pathway. Cell Death Differ 2003; 10: 850-852.
28. Ruester C, Bondeva T, Franke S et al. Advance glycation endproducts induce cell cycle arrest and hypertrophy in podocytes. Nephrol Dial Transplant 2008; 23: 2179-2191.
29. Cohen MP, Clements RS, Hud E et al. Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy. Exp Nephrol 1996; 4: 166-171.
30. Cohen CD, Frach K, Schlondorff D et al. Quantitative gene expression analysis in renal biopsies: a novel protocol for a high-throughput multicenter application. Kidney Int 2002; 61: 133-140.
31. Gerth J, Cohen CD, Hopfer U et al. Collagen type VIII expression in human diabetic nephropathy. Eur J Clin Invest 2007; 37: 767-773.
32. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147.
33. Kip1 in diabetic db/db mouse: role of hyperglycemia. Kidney Int 1998; 53: 869-879.
34. Cohen MP, Ziyadeh FN, Hong SW et al. Inhibiting albumin glycation in vivo ameliorates glomerular overexpression of TGF-β1. Kidney Int 2002; 61: 2025-2032.
35. Yuan L, Moyon D, Pardanaud L et al. Abnormal lymphatic vessel development in neuropilin 2 mutants mice. Development 2002; 129: 4797-4806.
36. Villegas G, Tufro A. Ontogeny of semaphorins 3A and 3F and their receptors neuropilins 1 and 2 in the kidney. Mech Dev 2002; 119S: S149-S153.
37. Takashima S, Kitakaze M, Asakura M et al. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci USA 2002; 99: 3657-3662.
38. Staton CA, Kumar I, Reed MW et al. Neuropilins in physiological and pathological angiogenesis. J Pathol 2007; 212: 237-248.
39. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem 2000; 275: 26690-26695.
40. Soker S, Takashima S, Miao HQ et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735-745.
41. Wharram BL, Goyal M, Wiggins JE et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005; 16: 2941-2952.
42. Guan F, Villegas G, Teichman J et al. Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol 2006; 291: F422-F428.
43. Cohen MP, Lautenslager GT, Hud E et al. Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency. Am J Physiol Renal Physiol 2007; 292: F789-F795.
44. Tapia R, Guan F, Gershin I et al. Semaphorin 3a disrupts podocyte foot processes causing acute proteinuria. Kidney Int 2008; 73: 733-740.
45. Shankland SJ, Pippin JW, Reiser J et al. Podocytes in culture: past, present, and future. Kidney Int 2007; 72: 26-36.
46. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
47. Panzer U, Thaiss F, Zahner G et al. Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis. Kidney Int 2001; 59: 1762-1769.